{"result": "(\"entity\"<|>ECHA<|>ORGANIZATION<|>ECHA refers to a condition related to hepatic encephalopathy, which involves multiple deficiencies of micronutrients and requires careful nutritional management.)\n##\n(\"entity\"<|>AACR<|>ORGANIZATION<|>AACR stands for branched-chain amino acids, which may contribute to the improvement of hepatic encephalopathy.)\n##\n(\"entity\"<|>ISOLUCINE<|>ORGANIZATION<|>Isoleucine is a branched-chain amino acid that serves as an anaplerotic substrate, potentially helping to remove ammonia in patients with sarcopenia.)\n##\n(\"entity\"<|>VALINE<|>ORGANIZATION<|>Valine is another branched-chain amino acid that can act as an anaplerotic substrate, aiding in the management of sarcopenia.)\n##\n(\"entity\"<|>VITAMIN D<|>PERSON<|>Vitamin D is a fat-soluble vitamin that is frequently deficient in patients with hepatic conditions, affecting up to 90% of such patients.)\n##\n(\"entity\"<|>ZINC<|>PERSON<|>Zinc is a micronutrient that is often deficient in patients with cirrhosis and can improve amino acid metabolism and encephalopathy when supplemented.)\n##\n(\"entity\"<|>SELENIUM<|>PERSON<|>Selenium is another micronutrient that may be deficient in patients with cirrhosis, both alcoholic and non-alcoholic.)\n##\n(\"entity\"<|>MAGNESIUM<|>PERSON<|>Magnesium is frequently deficient in patients with alcoholic liver disease and is important for overall health.)\n##\n(\"entity\"<|>ACID FOLIC<|>PERSON<|>Folic acid deficiency is common in patients with alcohol-related liver disease and requires monitoring and supplementation.)\n##\n(\"entity\"<|>TIAMINA<|>PERSON<|>Thiamine is often deficient in patients with liver disease, particularly those with a history of alcohol use.)\n##\n(\"entity\"<|>NUTRICIÓN ENTERAL<|>EVENT<|>Enteral nutrition is a method of providing nutrition to patients who cannot maintain adequate oral intake, often through a flexible feeding tube.)\n##\n(\"entity\"<|>NUTRICIÓN ORAL<|>EVENT<|>Oral nutrition refers to the intake of food and nutrients through the mouth, which is preferred when possible for patients.)\n##\n(\"relationship\"<|>ECHA<|>AACR<|>AACR supplementation may help improve the condition of patients with ECHA<|>7)\n##\n(\"relationship\"<|>ISOLUCINE<|>ECHA<|>Isoleucine is relevant in the context of ECHA as it helps in managing sarcopenia associated with the condition<|>6)\n##\n(\"relationship\"<|>VALINE<|>ECHA<|>Valine is also relevant in the context of ECHA for its role in managing sarcopenia<|>6)\n##\n(\"relationship\"<|>VITAMIN D<|>ECHA<|>Vitamin D deficiency is a common issue in patients with ECHA, necessitating monitoring and supplementation<|>8)\n##\n(\"relationship\"<|>ZINC<|>ECHA<|>Zinc supplementation can be beneficial for patients with ECHA, improving their metabolic state<|>7)\n##\n(\"relationship\"<|>SELENIUM<|>ECHA<|>Selenium deficiency is noted in patients with ECHA, indicating a need for monitoring<|>5)\n##\n(\"relationship\"<|>MAGNESIUM<|>ECHA<|>Magnesium deficiency is common in patients with ECHA, highlighting the importance of supplementation<|>5)\n##\n(\"relationship\"<|>ACID FOLIC<|>ECHA<|>Folic acid deficiency is prevalent in patients with ECHA, requiring attention and supplementation<|>5)\n##\n(\"relationship\"<|>TIAMINA<|>ECHA<|>Thiamine deficiency is a concern in patients with ECHA, necessitating monitoring<|>5)\n##\n(\"relationship\"<|>NUTRICIÓN ENTERAL<|>ECHA<|>Enteral nutrition is considered when oral intake is insufficient in patients with ECHA<|>6)\n##\n(\"relationship\"<|>NUTRICIÓN ORAL<|>ECHA<|>Oral nutrition is the preferred method of intake for patients with ECHA when feasible<|>6)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: empeorar el estado nutricional sin mejorar la encefalopatía hepática. Es una práctica errónea común prescribir restricción proteica a pacientes con encefalopatía hepática, en la creencia de que las proteínas contribuyen al mantenimiento de la encefalopatía132, 133. Es perjudicial y contribuye a un aumento del catabolismo proteico134. Pacientes con cirrosis hepática y encefalopatía episódica toleran dieta sin restricción de proteínas135 desde el momento en que se inicia el tratamiento de la misma. De hecho, una adecuada nutrición, por sí misma, puede contrarrestar la encefalopatía hepática. Se desaconseja encarecidamente restringir a menos de 1 g/kg día de proteína. En el caso de pacientes que parecen no tolerar más de esa cantidad, a menudo los síntomas se acaban resolviendo al descubrir un desencadenante oculto de encefalopatía (sangrado, no cumplimiento terapéutico, abuso de sustancias, etc.). La suplementación con AACR puede contribuir a la mejoría de la encefalopatía 136, aunque no han sido comparados frente a otras medidas antiencefalopatía. Sustituir las proteínas de origen animal por las de origen vegetal, más ricas en AACR y acompañadas de fibra prebiótica, podría tener utilidad118.\n\nLos aminoácidos ramificados podrían constituir una opción terapéutica basada en la fisiopatología. Isoleucina y valina son sustratos anapleuróticos, que pueden retirar amonio, mediador de la sarcopenia, y por tanto revertir la misma137. En pacientes sarcopénicos, la suplementación con AACR 12 g al día, mejora la supervivencia106.\n\n### 10.4. Suplementos vitamínicos y minerales\n\nLos pacientes con ECHA tienen riesgo de múltiples deficiencias de micronutrientes, como se ha mencionado anteriormente.\n\nLa deficiencia de vitaminas liposolubles puede presentarse en pacientes con esteatorrea por colestasis o deficiencia de sales biliares y en pacientes con etilismo138, aunque pueden estar presentes también en pacientes sin colestasis139. Se recomienda monitorizar niveles de vitaminas liposolubles, y suplementar las deficiencias. El más frecuente es el de vitamina D, como se ha referido anteriormente, presente hasta en un 90% de los pacientes97. Los niveles séricos de vitamina A pueden no correlacionar con los niveles hepáticos de la misma140. Puesto que los niveles hepáticos elevados de vitamina A pueden empeorar la función hepática, se debe tener cuidado con el aporte de vitamina A basándose tan solo en los niveles séricos de la misma141.\n\nLa depleción de vitaminas hidrosolubles es frecuente, especialmente en pacientes con enfermedad hepática etílica142.\n\nEl déficit de zinc y de selenio se ha observado en pacientes con cirrosis, tanto de origen alcohólico como no143, 144. El déficit de zinc es frecuente en pacientes con ECHA145, y su suplementación, cuando existe déficit, puede ser beneficiosa, con mejoría del metabolismo de aminoácidos y del grado de encefalopatía146, 147.\n\nEl manganeso puede acumularse en pacientes cirróticos y parece prudente no dar suplementos que lo contengan118.\n\nEn pacientes con etilismo son frecuentes las deficiencias de ácido fólico, magnesio, zinc y tiamina. En pacientes con descompensación cirrótica o en riesgo de malnutrición, está justificado el tratamiento con un preparado polivitamínico durante dos semanas118.\n\nNutrición enteral. Si la ingesta oral continúa siendo insuficiente, se considerará la nutrición enteral a través de una sonda flexible de pequeño calibre90. Este tipo de sondas no aumentan el riesgo de sangrado por varices esofágicas148. El sangrado digestivo lento o intermitente no es una contraindicación para la nutrición enteral.\n\nUna opción aceptable es proveer la nutrición enteral durante la noche, permitiendo la ingesta oral durante el día. No se recomienda la colocación de gastrostomías o yeyunostomías en pacientes con ascitis, por el riesgo de complicaciones tales como peritonitis o fístula de líquido ascítico149.\n\nSe deben evitar períodos prolongados sin soporte nutricional, dada la dificultad en mantener y reponer el estado nutricional.\n\nEn pacientes con retención de líquidos la fórmula enteral será preferiblemente energética (1,5 kcal/ml)150.\n\nEs importante descartar la presencia de malabsorción, sobre todo en pacientes con colestasis y etilismo con posible insuficiencia pancreática. De ser así, habrá que considerar el uso de fórmulas oligoméricas, aceite MCT\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}